Recent organic drug molecules designing for HIV infections and status of current progress in HIV therapy

The organic drug molecules synthesized target the biocycle of HIV at various stages. The common drug targets are fusion inhibitors, reverse transcriptase inhibitors (NRTI and NNRTIs), Integrase inhibitors and protease inhibitors. Herein is discussed the recent organic molecules designing and synthesis progress that targets these stages. The newer retroviral drugs and molecules under clinical trial discussed here include NRTIs (Festinavir (BMS-986001), amdoxovir, elvucitabine, apricitabine, racivir), NNRTIs (etravirine, rilpivirine), microbicides (UC-781 (Thiocarboxanilide), TMC-120 (Dapivirine), MIV-150), protease inhibitors (darunavir, tipranavir), fusion and entry inhibitors (enfuvirtide, sifuvirtide, AMD-070, BMS-663068, Cenicriviroc, INCB-9471, BMS-488043), CCR5 inhibitors (maraviroc, vicriviroc, PRO 140, PRO 542), CD4-receptor inhibitors (ibalizumab), integrase inhibitors (raltegravir, elvitegravir, GSK-1349572), maturation inhibitors (bevirimat), LEDGINs. Further details include progress in Gene therapy (siRNA), Vaccine development and progress in genetic and immune therapy for HIV treatment.